DBV Technologies 股價、新聞與催化劑

股票表現

股價為何變動

As of Aug 17, 2026, DBVT closed up 4.64% at $14.67. No new same-company headline was identified in the current news window.

公司概覽

未來催化劑

• DBV’s catalysts are Viaskin Peanut and any FDA or clinical step that keeps the food-allergy franchise alive. The next regulatory update matters because the company has spent years trying to bring the patch platform across the finish line.

近期新聞

1. 01
   2016-07-05 05:34 EST

   DBV Technologies Proudly Welcomes Dr. Lucia Septien as Chief Medical Officer

2. 02
   2016-06-21 20:32 EST

   DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Mailys Ferrere

3. 03
   2016-06-15 20:34 EST

   DBV Technologies: Late-Breaking Presentation at EAACI Highlights Viaskin(r) Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression

4. 04
   2016-06-13 05:36 EST

   DBV Technologies Announces Publication of Preclinical Data in JACI Suggesting EPIT(r) Provides Sustained Protection Against Anaphylaxis

5. 05
   2016-05-31 05:06 EST

   DBV Technologies and Nestle Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy

相似股票

商業成熟度、治療領域或催化劑模式相近的同業公司。